Clinical Trial Update: 12-Month Real-World Safety & Efficacy of Lecanemab in Early Alzheimer's Disease [Phase 4]

View source ↗

Summary

This Phase 4 trial update reports 12-month real-world safety and efficacy data for lecanemab in early Alzheimer's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Lecanemab (lecanemab)

Snippet

Sponsor: Ruijin Hospital | Conditions: Alzheimer's Disease(AD) | Phase 4 | Status: ACTIVE_NOT_RECRUITING